Drug-induced PML: A global agenda for a global challenge

M. Vinhas De Souza, B. Keller-Stanislawski, K. Blake, A. Hidalgo-Simon, P. Arlett, G. Dal Pan

Research output: Contribution to journalArticle

Abstract

The occurrence of severe adverse events such as progressive multifocal leukoencephalopathy (PML) has the potential to limit the benefits of highly efficacious medicines being developed to fulfill unmet clinical needs across therapeutic areas. Following an Expert meeting in London in July 2011 (http://www.ema.europa.eu/docs/en-GB/document-library/Report/2011/09/ WC500111562.pdf), a research agenda, highlighting methodological, clinical, and communication elements, to mitigate the risk and improve the management of drug-induced PML has been agreed upon.

Original languageEnglish (US)
Pages (from-to)747-750
Number of pages4
JournalClinical Pharmacology and Therapeutics
Volume91
Issue number4
DOIs
StatePublished - Apr 2012
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Drug-induced PML: A global agenda for a global challenge'. Together they form a unique fingerprint.

  • Cite this

    Vinhas De Souza, M., Keller-Stanislawski, B., Blake, K., Hidalgo-Simon, A., Arlett, P., & Dal Pan, G. (2012). Drug-induced PML: A global agenda for a global challenge. Clinical Pharmacology and Therapeutics, 91(4), 747-750. https://doi.org/10.1038/clpt.2012.4